Middle East & AfricaENPublic regulatory overview
Egypt
Market Overview Population: Approximately 107 million (2024), the secondmost populous country in Africa and the largest population market in the MENA region Healthcare System: Pred...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.
Reference approval strategy
FDA / CE / MDSAP / NMPA benefits for this market
These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.
US FDA
510(k) / De Novo / PMAStrong benefitFDA evidence can materially improve review confidence and may support verification, abridged, or reliance-style pathways.
Likely benefit
- Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
- May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
- Does not remove local holder, language, labeling, fee, import, or post-market obligations.
EU CE
MDR / IVDRStrong benefitCE documentation is highly reusable and may support reference, reliance, or overseas conformity assessment routes.
Likely benefit
- Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
- Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
- Does not replace local registration or local representative responsibilities outside the CE-recognized route.
MDSAP
Single QMS auditIndirect QMS signalMDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.
Likely benefit
- Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
- Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
- Does not authorize product sale and does not replace safety, performance, or clinical evidence.
China NMPA
China registration / filingPartial / emerging acceptanceNMPA is an emerging reference factor here: it may be accepted or considered for selected products, documents, or review discussions, but the scope must be verified before filing.
Likely benefit
- Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
- Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
- Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
AI Citation Summary
- Country: Egypt
- Product line: Medical devices
- Regulator / source: Regulatory Maturity: Medium; in 2021, the Egyptian Drug Authority (EDA) integrated the functions of the former CAPA, becoming the unified medical product regulatory body; the regulatory framework is in the process of modernization, but procedures remain complex
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
- Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
- Local requirement: Official Portal: https://www.eda.mohp.gov.eg (primarily Arabic, with some English content); online submission: EDA online registration system (recommended to operate through a local agent)
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Market Overview
- Population: Approximately 107 million (2024), the second-most populous country in Africa and the largest population market in the MENA region
- Healthcare System: Predominantly public hospital system (under the Ministry of Health and Population, MOHP); private healthcare is growing rapidly; Universal Health Coverage (UHC) reform is progressing (the 2018 Universal Health Insurance Law is being implemented gradually); healthcare resources are concentrated in Cairo, Alexandria, and other major cities
- Market Characteristics: Government procurement is the primary channel for medical devices; price competition is intense; private clinics/hospitals are growing rapidly; high import dependence; government policy favors domestic manufacturing; historical foreign exchange controls have affected imports
- Regulatory Maturity: Medium; in 2021, the Egyptian Drug Authority (EDA) integrated the functions of the former CAPA, becoming the unified medical product regulatory body; the regulatory framework is in the process of modernization, but procedures remain complex
Regulatory Authority
- Competent Authority: Egyptian Drug Authority (EDA), subordinate to the Ministry of Health and Population (MOHP); EDA's Medical Devices Registration Department handles specific registration matters
- Official Portal: https://www.eda.mohp.gov.eg (primarily Arabic, with some English content); online submission: EDA online registration system (recommended to operate through a local agent)
- Key Regulations:
- EDA Establishment Law (Law No. 151 of 2019 and its implementing regulations, 2021)
- Medical Devices Registration Requirements (EDA medical device registration regulations)
- Ministerial Decree 425/2019 (device classification and registration requirements)
- Import Regulation (import permit regulations, coordinated with GASC/Customs)
- GHTF/IMDRF framework as locally adapted and applied in Egypt
Device Classification System
| Local Class | Risk Level | EU Equivalent | FDA Equivalent | Description |
|---|---|---|---|---|
| Class I | Low risk | EU Class I / FDA Class I | Basic registration; relatively simple document requirements | |
| Class II | Low-medium risk | EU Class IIa / FDA Class II | Standard registration; Technical File required | |
| Class III | Medium-high risk | EU Class IIb / FDA Class II–III | Full technical review; relatively strong clinical evidence required | |
| Class IV | High risk | EU Class III / FDA Class III | Most rigorous review; complete clinical data required |
Classification follows GHTF classification principles (SG1 N15 and other guidance documents); some product categories have Egypt-specific classification interpretations.
Registration Pathways
During the limited-time free period, sign in or register to view the complete medical device country report.